Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)

Exclusion Criteria

• •Has a lower respiratory tract infection or has a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment
• •Has a coexisting infection or systemic mycosis for which there are no effective antibiotics
• •Has asthma that is under treatment and/or uncontrolled
• •Has nasal septum ulcers, nasal surgery, or nasal trauma which have not healed
• •Has vasomotor rhinitis or eosinophilic rhinitis
• •Has a history of hypersensitivity to antihistamines or ingredients of study drug
• •Has had treatment with corticosteroids (oral, injectable, suppository, depot drugs \[injectable\]) or immunological drugs within 28 days prior to Visit 2
• •Is currently receiving treatment with another investigational drug or has received an investigational drug within prior 3 months
• •Has started specific desensitization therapy (allergen immunotherapy) or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who has received such therapies within prior 3 months
• •Has received coagulation or resection using laser therapy etc. for treatment for nasal symptoms
• •Will receive nasal nebulizer therapy and/or thermotherapy during study period
• •Has severe hepatic, renal, cardiac, hematological disease, or other serious coexisting diseases and whose general condition is poor
• •Has a history of malignancy or clinically important hematological disorder, except for adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix
• •Has a history of severe drug allergy (e.g. anaphylactoid reaction)
• •Is pregnant or lactating or may be pregnant
• •Is planning a remote trip for more than 1 day during the Symptom Confirmation Period or for more than 2 days during the Treatment Period.